A multicenter, randomized, double-blind, parallel arm, 6-week study to evaluate the efficacy and safety of ezetimibe/simvastatin versus atorvastatin in patients with metabolic syndrome and hypercholesterolemia at high risk for coronary heart disease.

Trial Profile

A multicenter, randomized, double-blind, parallel arm, 6-week study to evaluate the efficacy and safety of ezetimibe/simvastatin versus atorvastatin in patients with metabolic syndrome and hypercholesterolemia at high risk for coronary heart disease.

Completed
Phase of Trial: Phase III

Latest Information Update: 18 Apr 2017

At a glance

  • Drugs Ezetimibe/simvastatin (Primary) ; Atorvastatin
  • Indications Hypercholesterolaemia; Metabolic syndrome
  • Focus Pharmacodynamics; Therapeutic Use
  • Acronyms VYMET
  • Sponsors Merck & Co
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 27 Jul 2009 Results were presented at the 15th International Symposium on Atherosclerosis (ISA) in Boston, MA.
    • 14 Sep 2008 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top